Icu Medical Intrinsic Stock Value – ICU Medical Reports FY2023 Q2 Earnings of $549.3M, 2.1% Drop Y-o-Y
August 11, 2023
🌧️Earnings Overview
ICU ($NASDAQ:ICUI) Medical announced their fiscal year 2023 second-quarter earnings results on June 30th 2023, reporting total revenue of USD 549.3 million, a 2.1% decrease compared to the same period in the previous year. Net income for the quarter was USD -9.9 million, a decrease from FY2022 Q2’s figure of -7.5 million.
Analysis – Icu Medical Intrinsic Stock Value
GoodWhale has conducted an analysis of ICU MEDICAL‘s fundamentals and determined a fair value of $261.4 per share for the company. This is calculated using GoodWhale’s proprietary Valuation Line, which takes into account a variety of factors such as the company’s financials, market performance, and other relevant metrics. Currently, ICU MEDICAL shares are trading at $171.4, which represents a 34.4% discount from the fair value determined by GoodWhale. This implies that ICU MEDICAL stock is currently undervalued and presents an attractive investment opportunity. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Icu Medical. More…
| Total Revenues | Net Income | Net Margin |
| 2.29k | -48.49 | -0.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Icu Medical. More…
| Operations | Investing | Financing |
| 40.37 | -69.31 | -29.59 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Icu Medical. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 4.46k | 2.35k | 87.74 |
Key Ratios Snapshot
Some of the financial key ratios for Icu Medical are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 22.3% | -25.2% | 0.5% |
| FCF Margin | ROE | ROA |
| -1.9% | 0.4% | 0.2% |
Peers
It operates in a highly competitive market that includes major competitors such as Ypsomed Holding AG, Coloplast A/S, and Cardiovascular Systems Inc. These companies all strive to provide the best quality products and services to meet the needs of their customers.
– Ypsomed Holding AG ($LTS:0QLQ)
Ypsomed Holding AG is a leading Swiss medical technology company that designs, develops, and manufactures healthcare products for delivery of drugs and other treatments. The company has a market capitalization of 2.34 billion as of 2022, reflecting the confidence of investors in the company’s potential and its ability to grow in the coming years. Ypsomed Holding AG also has a Return on Equity of 4.93%, which is a measure of the company’s profitability relative to its shareholders’ equity. This indicates that the company is using its resources efficiently and delivering value to its shareholders.
– Coloplast A/S ($LTS:0QBO)
Coloplast A/S is a Danish medical device company that develops, manufactures, and markets medical products and services worldwide. The company has a market cap of 183.14B as of 2022 and a Return on Equity (ROE) of 50.58%. The market cap is an indication of the overall size of the company and its potential to generate profits. A high ROE indicates that the company is able to generate a significant return on the invested capital, making it an attractive investment. Coloplast is known for its products and services in the areas of urology, continence care, ostomy care, and wound and skin care, which have helped to ensure the company’s continued success.
– Cardiovascular Systems Inc ($NASDAQ:CSII)
Cardiovascular Systems Inc is a medical device company that develops, manufactures, and markets innovative interventional treatment systems for peripheral and coronary artery disease. The company has a market cap of 576.3M as of 2022 and a Return on Equity of -9.45%. This indicates that the company is not generating enough profits to cover its costs, which is not a good sign for the investors. Despite this, the company continues to innovate and develop new products in order to improve its financial performance.
Summary
Investing analysis of ICU Medical, Inc. shows a downturn in the company’s performance for FY2023 Q2, with total revenue of USD 549.3 million, a 2.1% decrease year-on-year. Net income for the second quarter was USD -9.9 million, a lower figure than what was seen in the same period in the previous year at -7.5 million. This suggests a potential decline in investor confidence and profitability. It is important to review the company’s other performance metrics to better understand the outlook for the company and its potential future investments.
Related Posts
Recent Posts
